Ami Fadia
Stock Analyst at Needham
(4.41)
# 294
Out of 5,182 analysts
352
Total ratings
45.91%
Success rate
23.82%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Downgrades: Hold | n/a | $39.69 | - | 2 | Mar 31, 2026 | |
| NMRA Neumora Therapeutics | Reiterates: Buy | $8 | $2.00 | +300.00% | 11 | Mar 31, 2026 | |
| BCYC Bicycle Therapeutics | Maintains: Buy | $24 → $15 | $5.05 | +197.03% | 22 | Mar 18, 2026 | |
| ATAI AtaiBeckley | Reiterates: Buy | $14 | $3.79 | +269.39% | 2 | Mar 9, 2026 | |
| IMRX Immuneering | Reiterates: Buy | $11 | $5.45 | +101.83% | 21 | Mar 9, 2026 | |
| DAWN Day One Biopharmaceuticals | Downgrades: Hold | n/a | $21.45 | - | 24 | Mar 6, 2026 | |
| GHRS GH Research | Maintains: Buy | $31 → $32 | $14.57 | +119.63% | 4 | Mar 6, 2026 | |
| RVMD Revolution Medicines | Maintains: Buy | $150 → $145 | $99.12 | +46.29% | 28 | Feb 26, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $46 → $44 | $27.74 | +58.62% | 40 | Feb 25, 2026 | |
| AXSM Axsome Therapeutics | Reiterates: Buy | $225 | $168.51 | +33.53% | 19 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $187 → $185 | $131.60 | +40.58% | 17 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $510 | $310.38 | +64.31% | 17 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $235 | $186.95 | +25.70% | 35 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $35.21 | - | 24 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $29 | $22.20 | +30.66% | 12 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $44 | $34.84 | +26.29% | 4 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $177.34 | - | 43 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $240 → $320 | $14.74 | +2,070.96% | 2 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $63 → $75 | $22.70 | +230.40% | 7 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $10.85 | +480.65% | 5 | Sep 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $30.08 | - | 9 | Oct 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $0.80 | +2,652.75% | 4 | Jan 3, 2018 |
Centessa Pharmaceuticals
Mar 31, 2026
Downgrades: Hold
Price Target: n/a
Current: $39.69
Upside: -
Neumora Therapeutics
Mar 31, 2026
Reiterates: Buy
Price Target: $8
Current: $2.00
Upside: +300.00%
Bicycle Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $24 → $15
Current: $5.05
Upside: +197.03%
AtaiBeckley
Mar 9, 2026
Reiterates: Buy
Price Target: $14
Current: $3.79
Upside: +269.39%
Immuneering
Mar 9, 2026
Reiterates: Buy
Price Target: $11
Current: $5.45
Upside: +101.83%
Day One Biopharmaceuticals
Mar 6, 2026
Downgrades: Hold
Price Target: n/a
Current: $21.45
Upside: -
GH Research
Mar 6, 2026
Maintains: Buy
Price Target: $31 → $32
Current: $14.57
Upside: +119.63%
Revolution Medicines
Feb 26, 2026
Maintains: Buy
Price Target: $150 → $145
Current: $99.12
Upside: +46.29%
Harmony Biosciences Holdings
Feb 25, 2026
Maintains: Buy
Price Target: $46 → $44
Current: $27.74
Upside: +58.62%
Axsome Therapeutics
Feb 23, 2026
Reiterates: Buy
Price Target: $225
Current: $168.51
Upside: +33.53%
Feb 12, 2026
Maintains: Buy
Price Target: $187 → $185
Current: $131.60
Upside: +40.58%
Feb 4, 2026
Maintains: Buy
Price Target: $460 → $510
Current: $310.38
Upside: +64.31%
Jan 12, 2026
Maintains: Buy
Price Target: $210 → $235
Current: $186.95
Upside: +25.70%
Dec 8, 2025
Reiterates: Hold
Price Target: n/a
Current: $35.21
Upside: -
Nov 6, 2025
Maintains: Buy
Price Target: $28 → $29
Current: $22.20
Upside: +30.66%
Oct 29, 2025
Maintains: Buy
Price Target: $43 → $44
Current: $34.84
Upside: +26.29%
Sep 24, 2025
Reiterates: Hold
Price Target: n/a
Current: $177.34
Upside: -
Feb 1, 2021
Maintains: Outperform
Price Target: $240 → $320
Current: $14.74
Upside: +2,070.96%
Jan 21, 2021
Downgrades: Market Perform
Price Target: $63 → $75
Current: $22.70
Upside: +230.40%
Sep 17, 2020
Maintains: Outperform
Price Target: $64 → $63
Current: $10.85
Upside: +480.65%
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $30.08
Upside: -
Jan 3, 2018
Initiates: Outperform
Price Target: $22
Current: $0.80
Upside: +2,652.75%